



NEWS RELEASE

Ebola-specific monoclonal combination drug “ZMAb” extends treatment window to >1 day, study results published in Science Translational Medicine

Web Site Release

June 13, 2012

Toronto - Defyrus Inc. today announced a publication in Science Translational Medicine of a pioneering efficacy study lead by Dr. Gary Kobinger, Chief of Special Pathogens at the National Microbiology Laboratory (NML, Public Health Agency of Canada), which reports a significant medical breakthrough - the treatment of primates with lethal infections of Ebola virus. Improving on all previous drug candidates which needed to be given quickly, the ZMAb drug extends the treatment window to provide 100% efficacy when administered 1 day into the infection, additional benefit (50% survival) was reported when ZMAb was given 2 days into the otherwise lethal infection. Crucially, the ZMAb prevents viral shedding that is critical to constrain the spread of the contagion. “ZMAb” is a combination of 3 monoclonal antibodies that target 3 unique sites on the Ebola virus coat proteins, then by binding to them to disrupt the function of this lethal virus. These data highlight the important therapeutic role of antibodies to control Ebola virus replication and supports the use of MAbs against a severe filovirus infection.

“MAbs lead a fresh wave of treatment options against some of the most feared viral hemorrhagic fever viruses, and provide concrete solutions for the public health, biosafety and biosecurity sectors.” said Dr. Gary Kobinger.

Defyrus is addressing the commercial scale manufacture and clinical evaluation of ZMAb. “As the commercial developer of ZMAb, Defyrus Inc. welcomes this peer-review and publication of these important preclinical results of Drs. Qiu, Kobinger et al.” stated Jeffrey Turner, Ph.D, President and CEO, Defyrus Inc., “safe and effective Filovirus medical countermeasures are urgently needed and we are committed alongside our public sector partners at NML-PHAC to delivering ZMAb”.

About Defyrus

Defyrus is a private, life sciences biodefence company that collaborates with military and public health R&D partners in the United States, United Kingdom and Canada to develop broad spectrum anti-viral drugs, MAbs and immunopotentiators to improve vaccine performance as medical countermeasures to viral threats of military and public health interest.. www.defyrus.com

About NML

As Canada’s leading public health infectious disease laboratory, the National Microbiology Laboratory is responsible for the identification, control and prevention of infectious diseases. The NML is located at the Canadian Science Centre for Human and Animal Health, the first facility in the world to have high containment laboratories for human and animal health in one facility. It is recognized as a leading facility in an elite group of centres around the world, equipped with laboratories ranging from biosafety level 2 up to level 4 designed to accommodate the most deadly infectious organisms. www.nml-lnm.gc.ca



###

For further information:

Dr. Jeffrey D. Turner
President & CEO
Tel: (613) 674-1138
info@defyrus.com

Mr. Dana Rath
Chief Financial Officer
Tel: (514) 939-2531
info@defyrus.com